Camidge, D.R., Bang, Y.J., Kwak, E.L., et al. (2012) Activity and Safety of Crizotinib in Patients with ALK-Positive Non-Small-Cell Lung Cancer: Updated Results from a Phase 1 Study. Lancet Oncology, 13, 1011-1019.
http://dx.doi.org/10.1016/s1470-2045(12)70344-3

has been cited by the following article:

• TITLE: Development of Aseptic Renal Abscess in a Patient with Non-Small-Cell Lung Cancer with ALK Translocation during Crizotinib Treatment

  AUTHORS: Luciana Franco do Prado de Carvalho, Andrea Kazumi Shimada, Manuel Santos da Cruz Neto, Lucila Soares da Silva Rocha, Publio Cesar Cavalcante Viana, Esper George Kallas, Artur Katz

  KEYWORDS: Non-Small-Cell Lung Cancer, Crizotinib, Renal Abscesses

  JOURNAL NAME: Advances in Lung Cancer, Vol.4 No.4, February 29, 2016

  ABSTRACT: Background: Crizotinib is a tyrosine kinase inhibitor of ALK, MET and ROS1. In a safety database trial, it was suggested an association of Crizotinib with the development of renal cyst in patients with non-small-cell lung cancer (NSCLC). Aim: To report an uncommon side effect of Crizotinib in a patient with NSLC. Case Presentation: We report the case of a 68-year-old woman with NSCLC who developed bilateral progressive aseptic renal abscesses during Crizotinib treatment. Conclusion: Further studies may be necessary to determinate the risk of renal cyst development and the management of these complications.